Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Decoy TherapeuticsDCOY -3.68%23 ROC (Joel Greenblatt) % is -23,729.87% as of Mar. 2026. GuruFocus rates DCOY with a GF Score™ of 23/100. The stock has 3 warning signs investors should review. Among 1,323 Biotechnology companies, Decoy Therapeutics ranks worse than 95.77% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Decoy Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -23,729.87%.
The historical rank and industry rank for Decoy Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:
DCOY'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -55708.7 Med: -16692.93 Max: -7829.99
Current: -34233.77
During the past 12 years, Decoy Therapeutics's highest ROC (Joel Greenblatt) % was -7829.99%. The lowest was -55708.70%. And the median was -16692.93%.
DCOY's ROC (Joel Greenblatt) % is ranked worse than 95.77% of 1323
companies
in the Biotechnology industry
Industry Median: -291.64
vs DCOY: -34233.77
Decoy Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Decoy Therapeutics ROC (Joel Greenblatt) % Related Terms
Decoy Therapeutics ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Decoy Therapeutics's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DCOY vs PKTX, CASIF, VRAX: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, Decoy Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Decoy Therapeutics ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Decoy Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Decoy Therapeutics's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -23,729.87% mean?
Decoy Therapeutics (DCOY) has a ROC (Joel Greenblatt) % of -23,729.87% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Decoy Therapeutics and its competitors. According to the industry distribution chart, Decoy Therapeutics ranks #1267 out of 1323 companies in the Biotechnology industry, placing it in the top 95.8%.
Is Decoy Therapeutics' ROC (Joel Greenblatt) % too high?
Decoy Therapeutics' current ROC (Joel Greenblatt) % is -23,729.87%. Based on the distribution chart, Decoy Therapeutics ranks #1267 out of 1323 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Decoy Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Decoy Therapeutics' ROC (Joel Greenblatt) % compare to PKTX and CASIF?
According to the Biotechnology industry distribution chart, Decoy Therapeutics ranks #1267 out of 1323 companies for ROC (Joel Greenblatt) %. This places Decoy Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Decoy Therapeutics and its competitors. Decoy Therapeutics's current ROC (Joel Greenblatt) % is -23,729.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Decoy Therapeutics stock overvalued right now?
Decoy Therapeutics (DCOY) has a current ROC (Joel Greenblatt) % of -23,729.87%. The current ROC (Joel Greenblatt) % is -23,729.87%. Decoy Therapeutics' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Decoy Therapeutics (DCOY), the current ROC (Joel Greenblatt) % is -23,729.87% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.
23GF Score
Get the complete analysis for DCOY
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DCOY has been successfully added to your 
